3 Red Flags in Biotech Startup Pitch Decks Investors Miss
Biotech (Biotechnology) startups have sector-specific risk patterns that general-purpose due diligence frameworks miss. These 3 red flags are the ones experienced Biotech investors have learned to detect — often the hard way.
DDR automatically detects all 3 of these flags when you upload a Biotech startup pitch deck. See a sample report.
No composition-of-matter patent — only method patents
Method patents are weak protection. Composition-of-matter patents protect the molecule/therapy itself and are the foundation of biotech IP strategy.
Animal efficacy data in non-validated disease models
Many animal models don't predict human outcomes. Investors have been burned by companies with strong rodent data that failed in humans.
Lead scientist departing or not committed full-time
Biotech founding is inseparable from the scientific founder. Key scientist departure is catastrophic for clinical credibility and pipeline.
Positive Signals in Biotech Pitch Decks
Biotech Due Diligence — All Guides
Screen Any Biotech Startup in 5 Minutes
Upload a pitch deck PDF and DDR automatically runs this full due diligence framework — 13 OSINT sources, founder verification, all sector-specific red flags, comparable company analysis, and INVEST/PASS verdict.
GET YOUR FREE SCAN →